scholarly journals Interferon-ë rs12979860CC genotype predicts sustained virological response to therapy in patients with chronic hepatitis C Genotype 4 but enhances hepatic fibrosis

2016 ◽  
Vol 1 (2) ◽  
pp. 1-12
Author(s):  
Shiha G. ◽  
Samir W. ◽  
Seif S. ◽  
Soliman R. ◽  
Zalata K. ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Hepatic Fibrosis ◽  
Virological Response ◽  
Response To Therapy ◽  
Genotype 4

Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C

2008 ◽  
Vol 28 (8) ◽  
pp. 1112-1119 ◽  
Author(s):  
Rita Raafat Gad ◽  
Sylvia Males ◽  
Hesham El Makhzangy ◽  
Soheir Shouman ◽  
Aboubakr Hasan ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Genotype 4

scholarly journals Predictor factors of sustained virological response in patients with chronic hepatitis C treated with current direct-acting antiviral drugs

2020 ◽  
Vol 19 (9) ◽  
pp. 2015-2020
Author(s):  
Elwy M.K. Soliman ◽  
Hisham A.A. Morsy ◽  
Ashraf M.M. Othman ◽  
Ahmed M. Mady
Keyword(s):  
Chronic Hepatitis ◽  
Platelet Count ◽  
Hepatitis C ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Genotype 4 ◽  
Lower Baseline ◽  
Egyptian Patients ◽  
Cirrhotic Group

Purpose: To assess the efficacy and predictors of treatment response of chronic hepatitis C genotype 4 Egyptian patients with sofosbuvir and daclatasvir, with or without ribavirin.Methods: This prospective study enrolled 200 patients with chronic hepatitis C virus (HCV) genotype 4 infection who received sofosbuvir plus daclatasvir for 12 weeks, with the addition of ribavirin for treating cirrhotic patients. Immunological parameters such as natural killer (NK) cell percentage, phenotype, and serum C-X-C motif chemokine 10 (CXCL10) were evaluated prior to treatment and at the end of the treatment.Results: Overall, 92.5 % of the patients achieved sustained virological response at 12 weeks (SVR12), where the non-cirrhotic group had 96.29 % SVR12, while the cirrhotic group had 84.61 % SVR12. Nonresponders had lower pretreatment platelet count, higher CXCL10 levels, and lower baseline frequencies of NK cells and NK subgroup CD56- CD16+.Conclusion: Based on these results, the use of sofosbuvir plus daclatasvir with or without ribavirin for 12 weeks, is an effective regimen in the treatment of Egyptian patients infected with genotype 4 HCV. The predictors of non-response are advanced age, liver cirrhosis, lower pretreatment platelet count, higher level of CXCL10, lower baseline NK cells frequency and percentage of the dysfunctional subset CD56- CD16+. Keywords: Hepatitis C virus, Genotype 4, Sofosbuvir, Daclatasvir, Sustained virological response

scholarly journals Hepatitis C Therapy – Related Haematological Side Effects are Associated with Treatment Outcome / Hematološka Neželjena Dejstva Terapije Hepatitisa C Su Povezana Sa Ishodom Lecenja

2016 ◽  
Vol 17 (1) ◽  
pp. 9-14
Author(s):  
Vuk R. Vukovic ◽  
Dejan Baskic ◽  
Zeljko Mijailovic ◽  
Predrag Djurdjevic
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Side Effects ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Pegylated Interferon ◽  
Response To Therapy ◽  
Pegylated Interferon Alpha

Abstract Treatment of patients suffering from chronic hepatitis C with standard pegylated interferon alpha 2a plus ribavirin has limited efficacy. Therapy outcome is dependent on several factors of both the host and virus, including age, sex, stage of fibrosis, viral genotype, viral load, and occurrence of haematological adverse events during chronic hepatitis C treatment. The aim of this study was to determine the relationship between the viral and host factors and the haematological side effects of therapy with sustained virological response. Fifty-four patients were treated with combined pegylated interferon alpha 2a plus ribavirin therapy. Hepatitis C virus genotyping, viral load, histopathological liver changes and biochemical parameters were evaluated for each patient before beginning treatment. Each patient’s blood count was analysed during each clinical visit. Sustained virological response was achieved in 75,9% of patients. Baseline AST and ALT levels were significantly higher in patients with a poor response to therapy (p<0,05). Other clinical and laboratory parameters did not reach statistical significance. Both responders and non-responders developed anaemia. A decrease in thrombocytes, neutrophils and white blood cells was significantly associated with a sustained response to therapy (p<0,05, p<0,05 and p<0,001, respectively). Sustained virological response was associated with lower baseline AST and ALT values and thrombocytopenia, leucopenia and neutropenia at the end of the treatment. All treated patients developed anaemia.

scholarly journals Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis

JAMA ◽  
2012 ◽  
Vol 308 (24) ◽  
pp. 2584 ◽  
Author(s):  
Adriaan J. van der Meer ◽  
Bart J. Veldt ◽  
Jordan J. Feld ◽  
Heiner Wedemeyer ◽  
Jean-François Dufour ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Hepatic Fibrosis ◽  
Virological Response ◽  
All Cause Mortality

scholarly journals The impact of achieving a sustained virological response with direct-acting antivirals on serum autotaxin levels in chronic hepatitis C patients

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Shereen Abou Bakr Saleh ◽  
Khaled Mohamed Abdelwahab ◽  
Asmaa Mady Mady ◽  
Ghada Abdelrahman Mohamed
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Hepatic Fibrosis ◽  
Virological Response ◽  
Direct Acting Antivirals ◽  
Fibrosis Regression ◽  
Direct Acting ◽  
The Impact

Abstract Background Autotaxin (ATX) is an emerging biomarker for liver fibrosis. Achievement of sustained virological response (SVR) by direct-acting antivirals (DAAs) results in hepatic fibrosis regression in chronic hepatitis C (CHC) patients. In this context, the clinical implications of ATX have not yet been well-defined. In this study, we aimed to assess the impact of achieving SVR with DAA therapy on serum ATX levels and whether these levels can reflect the regression of hepatic fibrosis in CHC patients. We evaluated serum ATX levels at baseline and 12 weeks post-DAA therapy in 48 CHC patients. We compared ATX with FIB4 score and AST-to-Platelet Ratio Index (APRI) as regards the detection of grade F3–4 fibrosis. Results Serum ATX levels were significantly declined in 47 patients after the achievement of SVR12 (p < 0.001). The diagnostic ability of ATX for the detection of grade F3–4 fibrosis was inferior to FIB4 and APRI scores at baseline and SVR12. Conclusion Achievement of SVR with DAA therapy causes a significant decline in serum autotaxin concentrations, suggesting early regression of hepatic fibrosis in CHC patients. However, its diagnostic capability for routine patient monitoring and follow-up is still under debate.

Sign in / Sign up

Export Citation Format

Share Document